Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles
Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles
复制标题
DOI：
10.1016/j.vaccine.2009.09.047
复制
发表时间：
2010-04-01
期刊：
影响因子：
5.5
通讯作者：
Burke, Donald S.
中科院分区：
文献类型：
--
作者：
Lee, Bruce Y.;Burke, Donald S.
正如历史所证明的那样，批准后的障碍可能会阻碍疫苗的使用，并可能导致其撤回。在疫苗技术仍然可以很容易地改变的情况下解决这些潜在的障碍可能会提高疫苗的成功机会。增强的疫苗靶向产品概况（TPPs）可以帮助疫苗科学家更好地理解和预测这些障碍，并激发各种疫苗利益相关者之间的对话（例如，科学家、营销人员、业务发展经理、政策制定者、公共卫生官员、卫生保健工作者、第三方付款人等）在疫苗研发的早期(c)2009爱思唯尔有限公司保留所有权利。
As history has demonstrated, post-approval obstacles can impede a vaccine's use and potentially lead to its withdrawal. Addressing these potential obstacles when changes in a vaccine's technology can still be easily made may improve a vaccine's chances of success. Augmented vaccine target product profiles (TPPs) can help vaccine scientists better understand and anticipate these obstacles and galvanize conversations among various vaccine stakeholders (e.g., scientists, marketers, business development managers, policy makers, public health officials, health care workers, third party payors, etc.) earlier in a vaccine's development. (c) 2009 Elsevier Ltd. All rights reserved.